Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure. We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure. METHODS: Patients were randomly assigned to eplerenone (25 mg per day initially, titrated to a maximum of 50 mg per day; 3319 patients) or placebo (3313 patients) [correction] in addition to optimal medical therapy. The study continued until 1012 deaths occurred. The primary end points were death from any cause and death from cardiovascular causes or hospitalization for heart failure, acute myocardial infarction, stroke, or ventricular arrhythmia. RESULTS: During a mean follow-up of 16 months, there were 478 deaths in the eplerenone group and 554 deaths in the placebo group (relative risk, 0.85; 95 percent confidence interval, 0.75 to 0.96; P=0.008). Of these deaths, 407 in the eplerenone group and 483 in the placebo group were attributed to cardiovascular causes (relative risk, 0.83; 95 percent confidence interval, 0.72 to 0.94; P=0.005). The rate of the other primary end point, death from cardiovascular causes or hospitalization for cardiovascular events, was reduced by eplerenone (relative risk, 0.87; 95 percent confidence interval, 0.79 to 0.95; P=0.002), as was the secondary end point of death from any cause or any hospitalization (relative risk, 0.92; 95 percent confidence interval, 0.86 to 0.98; P=0.02). There was also a reduction in the rate of sudden death from cardiac causes (relative risk, 0.79; 95 percent confidence interval, 0.64 to 0.97; P=0.03). The rate of serious hyperkalemia was 5.5 percent in the eplerenone group and 3.9 percent in the placebo group (P=0.002), whereas the rate of hypokalemia was 8.4 percent in the eplerenone group and 13.1 percent in the placebo group (P<0.001). CONCLUSIONS: The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Randomized controlled trial data regarding in-hospital initiation of MRA therapy among patients with HFrEF is limited to the EPHESUS trial.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [38]
In the citing paper
“Mineralocorticoid receptor antagonists (spironolactone, eplerenone) can also be effective antihypertensive agents (particularly for those with borderline or low potassium levels)89 and are important for morbidity and mortality reduction in patients with left ventricular dysfunction.90,91”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [90]
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Self-citationDickstein, K., & Kjekshus, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09895-1 · Cited by 1,203
Calculating the number needed to treat for trials where the outcome is time to an event
Altman, D. G., & Andersen, P. K. (1999) · BMJ · doi:10.1136/bmj.319.7223.1492 · Cited by 710
Aldosterone induces a vascular inflammatory phenotype in the rat heart
Rocha, R., Rudolph, A. E., Frierdich, G. E., Nachowiak, D. A., Kekec, B. K., Blomme, E. A. G., McMahon, E. G., & Delyani, J. A. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01096.2001 · Cited by 655
Aldosterone-Induced Inflammation in the Rat Heart
Sun, Y., Zhang, J., Lu, L., Chen, S. S., Quinn, M. T., & Weber, K. T. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64454-9 · Cited by 567
Farquharson, C. A. J., & Struthers, A. D. (2000) · Circulation · doi:10.1161/01.cir.101.6.594 · Cited by 532
Pitt, B., Williams, G., Remme, W., Martinez, F., Lopez-Sendon, J., Zannad, F., Neaton, J., Roniker, B., Hurley, S., Burns, D., et al. (2001) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1011119003788 · Cited by 364
Self-citation
Research works printed but not linked: 3
- Rodriguez JA, 1997, Rev Med Chile, 125, 643
- Schaefer A, 2002, Eur Heart J, 23, 401
- de Gasparo M, 1987, J Pharmacol Exp Ther, 240, 650
Cited by
Items 101–200 of 1,018
Al-Khatib, S. M., Stevenson, W. G., Ackerman, M. J., Bryant, W. J., Callans, D. J., Curtis, A. B., Deal, B. J., Dickfeld, T., Field, M. E., Fonarow, G. C., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.10.053 · Cited by 678
Ezekowitz, J. A., O'Meara, E., McDonald, M. A., Abrams, H., Chan, M., Ducharme, A., Giannetti, N., Grzeslo, A., Hamilton, P. G., Heckman, G. A., et al. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.08.022 · Cited by 676
Executive Summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline
Heart Failure Society Of America (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2005.12.001 · Cited by 683
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · JACC · doi:10.1016/j.jacc.2024.11.009 · Cited by 552
Pfisterer, M., Buser, P., Rickli, H., Gutmann, M., Erne, P., Rickenbacher, P., Vuillomenet, A., Jeker, U., Dubach, P., Beer, H., et al. (2009) · JAMA · doi:10.1001/jama.2009.2 · Cited by 652
Frantz, S., Hundertmark, M. J., Schulz-Menger, J., Bengel, F. M., & Bauersachs, J. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac223 · Cited by 606
THE CARDIAC FIBROBLAST: Therapeutic Target in Myocardial Remodeling and Failure
Brown, R. D., Ambler, S. K., Mitchell, M. D., & Long, C. S. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095802 · Cited by 647
Jugdutt, B. I. (2003) · Circulation · doi:10.1161/01.cir.0000085658.98621.49 · Cited by 629
Al-Khatib, S. M., Stevenson, W. G., Ackerman, M. J., Bryant, W. J., Callans, D. J., Curtis, A. B., Deal, B. J., Dickfeld, T., Field, M. E., Fonarow, G. C., et al. (2018) · Heart Rhythm · doi:10.1016/j.hrthm.2017.10.036 · Cited by 629
Heart Failure After Myocardial Infarction: Incidence and Predictors
Jenča, D., Melenovský, V., Stehlik, J., Staněk, V., Kettner, J., Kautzner, J., Adámková, V., & Wohlfahrt, P. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13144 · Cited by 605
Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system
Palmer, B. F. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035279 · Cited by 640
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000691 · Cited by 639
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Agarwal, R., Kolkhof, P., Bakris, G., Bauersachs, J., Haller, H., Wada, T., & Zannad, F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa736 · Cited by 638
Self-citationAdrenergic Nervous System in Heart Failure: Pathophysiology and Therapy
Lymperopoulos, A., Rengo, G., & Koch, W. J. (2013) · Circulation Research · doi:10.1161/circresaha.113.300308 · Cited by 607
Aronow, W. S., Fleg, J. L., Pepine, C. J., Artinian, N. T., Bakris, G., Brown, A. S., Ferdinand, K. C., Forciea, M. A., Frishman, W. H., Jaigobin, C., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31821daaf6 · Cited by 614
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001309 · Cited by 625
Pitt, B., Kober, L., Ponikowski, P., Gheorghiade, M., Filippatos, G., Krum, H., Nowack, C., Kolkhof, P., Kim, S.-Y., & Zannad, F. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht187 · Cited by 591
Self-citationRapezzi, C., Biagini, E., & Branzi, A. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm498 · Cited by 595
Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update
Mosca, L., Banka, C. L., Benjamin, E. J., Berra, K., Bushnell, C., Dolor, R. J., Ganiats, T. G., Gomes, A. S., Gornik, H. L., Gracia, C., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.181546 · Cited by 579
Cardiovascular Outcomes in Patients With Primary Aldosteronism After Treatment
Catena, C. (2008) · Archives of Internal Medicine · doi:10.1001/archinternmed.2007.33 · Cited by 565
Goetze, J. P., Bruneau, B. G., Ramos, H. R., Ogawa, T., de Bold, M. K., & de Bold, A. J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0381-0 · Cited by 531
JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome
Kimura, K., Kimura, T., Ishihara, M., Nakagawa, Y., Nakao, K., Miyauchi, K., Sakamoto, T., Tsujita, K., Hagiwara, N., Miyazaki, S., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0133 · Cited by 565
Schocken, D. D., Benjamin, E. J., Fonarow, G. C., Krumholz, H. M., Levy, D., Mensah, G. A., Narula, J., Shor, E. S., Young, J. B., & Hong, Y. (2008) · Circulation · doi:10.1161/circulationaha.107.188965 · Cited by 552
Structural Overview of the Nuclear Receptor Superfamily: Insights into Physiology and Therapeutics
Huang, P., Chandra, V., & Rastinejad, F. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135917 · Cited by 533
Hunyady, L., & Catt, K. J. (2006) · Molecular Endocrinology · doi:10.1210/me.2004-0536 · Cited by 541
HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis
Tall, A. R., Yvan-Charvet, L., Terasaka, N., Pagler, T., & Wang, N. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.03.001 · Cited by 540
Solomon, S. D., Claggett, B., Lewis, E. F., Desai, A., Anand, I., Sweitzer, N. K., O'Meara, E., Shah, S. J., McKinlay, S., Fleg, J. L., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv464 · Cited by 532
Self-citationStructural and Functional Remodeling of the Left Atrium
Casaclang-Verzosa, G., Gersh, B. J., & Tsang, T. S. M. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.026 · Cited by 529
Glucocorticoids and cardiovascular disease
Walker, B. R. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0455 · Cited by 529
ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly
Aronow, W. S., Fleg, J. L., Pepine, C. J., Artinian, N. T., Bakris, G., Brown, A. S., Ferdinand, K. C., Ann Forciea, M., Frishman, W. H., Jaigobin, C., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.01.008 · Cited by 514
Mechanisms of sudden cardiac death
Rubart, M. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26381 · Cited by 504
Wright, R. S., Anderson, J. L., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., Jneid, H., Lincoff, A. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.02.011 · Cited by 516
Mant, J., Doust, J., Roalfe, A., Barton, P., Cowie, M., Glasziou, P., Mant, D., McManus, R., Holder, R., Deeks, J., et al. (2009) · Health Technology Assessment · doi:10.3310/hta13320 · Cited by 498
Central serous chorioretinopathy: Towards an evidence-based treatment guideline
van Rijssen, T. J., van Dijk, E. H. C., Yzer, S., Ohno-Matsui, K., Keunen, J. E. E., Schlingemann, R. O., Sivaprasad, S., Querques, G., Downes, S. M., Fauser, S., et al. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.07.003 · Cited by 478
Alexander, K. P., Newby, L. K., Armstrong, P. W., Cannon, C. P., Gibler, W. B., Rich, M. W., Van de Werf, F., White, H. D., Weaver, W. D., Naylor, M. D., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.182616 · Cited by 483
Ibánez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.11.010 · Cited by 461
The renin-angiotensin-aldosterone system and its suppression
Ames, M. K., Atkins, C. E., & Pitt, B. (2019) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.15454 · Cited by 433
Self-citationRenal Damage in Primary Aldosteronism: Results of the PAPY Study
Rossi, G. P., Bernini, G., Desideri, G., Fabris, B., Ferri, C., Giacchetti, G., Letizia, C., Maccario, M., Mannelli, M., Matterello, M.-J., et al. (2006) · Hypertension · doi:10.1161/01.hyp.0000230444.01215.6a · Cited by 470
Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis
Brown, N. J. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.110 · Cited by 451
McMurray, J. J. V. (2010) · New England Journal of Medicine · doi:10.1056/nejmcp0909392 · Cited by 455
Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes
Epstein, M., Williams, G. H., Weinberger, M., Lewin, A., Krause, S., Mukherjee, R., Patni, R., & Beckerman, B. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00240106 · Cited by 459
Heart Rate Turbulence: Standards of Measurement, Physiological Interpretation, and Clinical Use
Bauer, A., Malik, M., Schmidt, G., Barthel, P., Bonnemeier, H., Cygankiewicz, I., Guzik, P., Lombardi, F., Müller, A., Oto, A., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.07.041 · Cited by 462
Dzau, V. J., Antman, E. M., Black, H. R., Hayes, D. L., Manson, J. E., Plutzky, J., Popma, J. J., & Stevenson, W. (2006) · Circulation · doi:10.1161/circulationaha.106.655688 · Cited by 437
Filippatos, G., Anker, S. D., Böhm, M., Gheorghiade, M., Køber, L., Krum, H., Maggioni, A. P., Ponikowski, P., Voors, A. A., Zannad, F., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw132 · Cited by 446
Self-citationHFSA 2006 Comprehensive Heart Failure Practice Guideline: Introduction and Table of Contents
Heart Failure Society of America (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2005.11.005 · Cited by 452
The emerging role of ACE2 in physiology and disease
Hamming, I., Cooper, M., Haagmans, B., Hooper, N., Korstanje, R., Osterhaus, A., Timens, W., Turner, A., Navis, G., & van Goor, H. (2007) · The Journal of Pathology · doi:10.1002/path.2162 · Cited by 434
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II
Beckman, J. A., Paneni, F., Cosentino, F., & Creager, M. A. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht142 · Cited by 434
Kolkhof, P., Delbeck, M., Kretschmer, A., Steinke, W., Hartmann, E., Bärfacker, L., Eitner, F., Albrecht-Küpper, B., & Schäfer, S. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000091 · Cited by 430
The incidence and implications of aldosterone breakthrough
Bomback, A. S., & Klemmer, P. J. (2007) · Nature Clinical Practice Nephrology · doi:10.1038/ncpneph0575 · Cited by 420
Verrier (2011) · doi:10.1016/j.jacc.2011.06.029 · Cited by 421
2014 ESC/EACTS Guidelines on myocardial revascularization
Windecker, S., Kolh, P., Alfonso, F., Collet, J.-P., Cremer, J., Falk, V., Filippatos, G., Hamm, C., Head, S. J., Jüni, P., et al. (2014) · Kardiologia Polska · doi:10.5603/kp.2014.0224 · Cited by 418
Ersbøll, M., Valeur, N., Mogensen, U. M., Andersen, M. J., Møller, J. E., Velazquez, E. J., Hassager, C., Søgaard, P., & Køber, L. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.061 · Cited by 408
Al-Khatib, S. M., Stevenson, W. G., Ackerman, M. J., Bryant, W. J., Callans, D. J., Curtis, A. B., Deal, B. J., Dickfeld, T., Field, M. E., Fonarow, G. C., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000548 · Cited by 412
Underrepresentation of Renal Disease in Randomized Controlled Trials of Cardiovascular Disease
Coca, S. G., Krumholz, H. M., Garg, A. X., & Parikh, C. R. (2006) · JAMA · doi:10.1001/jama.296.11.1377 · Cited by 408
The Role of the Autonomic Nervous System in Sudden Cardiac Death
Vaseghi, M., & Shivkumar, K. (2008) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2008.01.003 · Cited by 396
Navigating the Crossroads of Coronary Artery Disease and Heart Failure
Gheorghiade, M., Sopko, G., De Luca, L., Velazquez, E. J., Parker, J. D., Binkley, P. F., Sadowski, Z., Golba, K. S., Prior, D. L., Rouleau, J. L., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.623199 · Cited by 402
Abbate, A., Van Tassell, B. W., Biondi-Zoccai, G., Kontos, M. C., Grizzard, J. D., Spillman, D. W., Oddi, C., Roberts, C. S., Melchior, R. D., Mueller, G. H., et al. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.01.287 · Cited by 393
Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure
Dei Cas, A., Khan, S. S., Butler, J., Mentz, R. J., Bonow, R. O., Avogaro, A., Tschoepe, D., Doehner, W., Greene, S. J., Senni, M., et al. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2014.08.004 · Cited by 401
Heart Failure–Associated Hospitalizations in the United States
Blecker, S., Paul, M., Taksler, G., Ogedegbe, G., & Katz, S. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.12.038 · Cited by 389
SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19?
Kuster, G. M., Pfister, O., Burkard, T., Zhou, Q., Twerenbold, R., Haaf, P., Widmer, A. F., & Osswald, S. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa235 · Cited by 395
Pitt, B., White, H., Nicolau, J., Martinez, F., Gheorghiade, M., Aschermann, M., van Veldhuisen, D. J., Zannad, F., Krum, H., Mukherjee, R., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.04.038 · Cited by 388
Self-citationLong-term Renal Outcomes in Patients With Primary Aldosteronism
Sechi, L. A., Novello, M., Lapenna, R., Baroselli, S., Nadalini, E., Colussi, G. L., & Catena, C. (2006) · JAMA · doi:10.1001/jama.295.22.2638 · Cited by 388
Mechanisms of Altered Ca 2+ Handling in Heart Failure
Luo, M., & Anderson, M. E. (2013) · Circulation Research · doi:10.1161/circresaha.113.301651 · Cited by 357
Acute Coronary Syndromes: Diagnosis and Management, Part I
Kumar, A., & Cannon, C. P. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.10.917 · Cited by 377
Seeger, F. H., Tonn, T., Krzossok, N., Zeiher, A. M., & Dimmeler, S. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl509 · Cited by 387
Diagnosis and treatment of primary aldosteronism
Reincke, M., Bancos, I., Mulatero, P., Scholl, U. I., Stowasser, M., & Williams, T. A. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00210-2 · Cited by 354
Jaffe, I. Z., & Mendelsohn, M. E. (2005) · Circulation Research · doi:10.1161/01.res.0000159937.05502.d1 · Cited by 358
Catena, C., Colussi, G., Lapenna, R., Nadalini, E., Chiuch, A., Gianfagna, P., & Sechi, L. A. (2007) · Hypertension · doi:10.1161/hypertensionaha.107.095448 · Cited by 358
2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2024) · European Heart Journal: Acute Cardiovascular Care · doi:10.1093/ehjacc/zuad107 · Cited by 314
Silver, M. A., Maisel, A., Yancy, C. W., McCullough, P. A., Burnett, J. C., Francis, G. S., Mehra, M. R., William Franklin Peacock IV, M., Fonarow, G., Gibler, W. B., et al. (2004) · Congestive Heart Failure · doi:10.1111/j.1527-5299.2004.03271.x · Cited by 361
Krumholz, H. M., Anderson, J. L., Brooks, N. H., Fesmire, F. M., Lambrew, C. T., Landrum, M. B., Weaver, W. D., Whyte, J., Bonow, R. O., Bennett, S. J., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.10.020 · Cited by 362
Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors
McCurley, A., Pires, P. W., Bender, S. B., Aronovitz, M., Zhao, M. J., Metzger, D., Chambon, P., Hill, M. A., Dorrance, A. M., Mendelsohn, M. E., et al. (2012) · Nature Medicine · doi:10.1038/nm.2891 · Cited by 347
What is the optimal serum potassium level in cardiovascular patients?
Macdonald, J. E., & Struthers, A. D. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.06.021 · Cited by 345
Kawase, Y., Ly, H. Q., Prunier, F., Lebeche, D., Shi, Y., Jin, H., Hadri, L., Yoneyama, R., Hoshino, K., Takewa, Y., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.12.014 · Cited by 344
Tissue Renin-Angiotensin-Aldosterone Systems: Targets for Pharmacological Therapy
Bader, M. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105610 · Cited by 345
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318212bb8b · Cited by 343
Sowers, J. R., Whaley-Connell, A., & Epstein, M. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-11-200906020-00005 · Cited by 351
Zannad, F., Mebazaa, A., Juillière, Y., Cohen-Solal, A., Guize, L., Alla, F., Rougé, P., Blin, P., Barlet, M.-H., Paolozzi, L., et al. (2006) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2006.01.001 · Cited by 354
Self-citationCardiorenal Syndrome Revisited
Zannad, F., & Rossignol, P. (2018) · Circulation · doi:10.1161/circulationaha.117.028814 · Cited by 335
Self-citationGuidelines for the management of arterial hypertension
van de Borne, P. (2014) · Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) · doi:10.2143/ac.69.1.3011345 · Cited by 350
Jaisser, F., & Farman, N. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011106 · Cited by 327
Aldosterone: effects on the kidney and cardiovascular system
Briet, M., & Schiffrin, E. L. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.30 · Cited by 337
Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up
Duboc, D., Meune, C., Pierre, B., Wahbi, K., Eymard, B., Toutain, A., Berard, C., Vaksmann, G., Weber, S., & Bécane, H.-M. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.05.014 · Cited by 343
Guo, C., Ricchiuti, V., Lian, B. Q., Yao, T. M., Coutinho, P., Romero, J. R., Li, J., Williams, G. H., & Adler, G. K. (2008) · Circulation · doi:10.1161/circulationaha.107.748640 · Cited by 342
The Mineralocorticoid Receptor: Insights into its Molecular and (Patho)Physiological Biology
Viengchareun, S., Le Menuet, D., Martinerie, L., Munier, M., Tallec, L. P.-L., & Lombès, M. (2007) · Nuclear Receptor Signaling · doi:10.1621/nrs.05012 · Cited by 316
Acute Coronary Syndromes: Diagnosis and Management, Part II
Kumar, A., & Cannon, C. P. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60674-5 · Cited by 336
2014 ESC/EACTS Guidelines on myocardial revascularization
Windecker, S., Kolh, P., Alfonso, F., Collet, J.-P., Cremer, J., Falk, V., Filippatos, G., Hamm, C., Head, S. J., Jüni, P., et al. (2015) · EuroIntervention · doi:10.4244/eijy14m09_01 · Cited by 328
Coronary Artery Disease in Patients ≥80 Years of Age
Madhavan, M. V., Gersh, B. J., Alexander, K. P., Granger, C. B., & Stone, G. W. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.12.068 · Cited by 320
Sex and Gender Differences in Myocarditis and Dilated Cardiomyopathy
Fairweather, D., Cooper, L. T., & Blauwet, L. A. (2013) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2012.07.003 · Cited by 325
Gender differences in the effects of cardiovascular drugs
Tamargo, J., Rosano, G., Walther, T., Duarte, J., Niessner, A., Kaski, J., Ceconi, C., Drexel, H., Kjeldsen, K., Savarese, G., et al. (2017) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw042 · Cited by 317
Johar, S., Cave, A. C., Narayanapanicker, A., Grieve, D. J., Shah, A. M., Johar, S., Cave, A. C., Narayanapanicker, A., Grieve, D. J., & Shah, A. M. (2006) · The FASEB Journal · doi:10.1096/fj.05-4642fje · Cited by 318
Aldosterone and end-organ damage
Brown, N. J. (2005) · Current Opinion in Nephrology and Hypertension · doi:10.1097/01.mnh.0000165889.60254.98 · Cited by 320
Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure
Swedberg, K., Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Shi, H., Vincent, J., & Pitt, B. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.11.063 · Cited by 313
Self-citationVolpe, M., Carnovali, M., & Mastromarino, V. (2015) · Clinical Science · doi:10.1042/cs20150469 · Cited by 305
5-Hydroxytryptamine receptors in the human cardiovascular system
Kaumann, A. J., & Levy, F. O. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.12.004 · Cited by 309
Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma
Fernandes-Rosa, F. L., Williams, T. A., Riester, A., Steichen, O., Beuschlein, F., Boulkroun, S., Strom, T. M., Monticone, S., Amar, L., Meatchi, T., et al. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.03419 · Cited by 310
Systematic Review: Cardiac Resynchronization in Patients with Symptomatic Heart Failure
McAlister, F. A., Ezekowitz, J. A., Wiebe, N., Rowe, B., Spooner, C., Crumley, E., Hartling, L., Klassen, T., & Abraham, W. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-5-200409070-00101 · Cited by 315
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
Effects of Aldosterone on the Vasculature
Schiffrin, E. L. (2006) · Hypertension · doi:10.1161/01.hyp.0000201443.63240.a7 · Cited by 303
Rossing, K., Schjoedt, K. J., Smidt, U. M., Boomsma, F., & Parving, H.-H. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2106 · Cited by 299
Metadata
- Authors
- Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M.
- Affiliations
- University of Michigan (US)
- Cardiovascular Research Foundation (US)
- University of Minnesota (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-03
- Volume
- 348
- Issue
- 14
- Pages
- 1309-1321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152094259
- Cited by
- 4,941
- References
- 27
- Citations by year
- 2026: 120 · 2025: 148 · 2024: 136 · 2023: 150 · 2022: 155 · 2021: 156 · 2020: 164 · 2019: 147 · 2018: 187 · 2017: 188 · 2016: 177 · 2015: 224 · 2014: 239 · 2013: 270 · 2012: 281
- FWCI
- 180.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- eplerenone, mineralocorticoid receptor antagonists, left ventricular dysfunction, myocardial infarction, heart failure, cardiovascular mortality, sudden cardiac death, hyperkalemia, hypokalemia, hospitalization, ventricular arrhythmias, mortality reduction, secondary prevention
- MeSH terms
- Eplerenone, Aged, Mineralocorticoid Receptor Antagonists, Blood Pressure, Double-Blind Method, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Myocardial Infarction, Potassium, Spironolactone, Survival Analysis, Death, Sudden, Cardiac, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.